Subscribe to our email list for the latest updates
Subscribe to our email list for the latest updates
RadioGel® is a division of Vivos Inc. and holds the patent for a next generation cancer treatment - Precision Radionuclide Therapy (PRnT)™
The future of cancer treatment – the insertion of our radionuclide device directly into the tumor tissue. RadioGel® is currently not approved for human use.
Our patented Precision Radionuclide Therapy™ is demonstrated in this video detailing how we kill a cancerous tumor from the inside out.
The technology is used in our IsoPet® treatment for small and large animals and for RadioGel® for treating cancer in humans.
RadioGel® is currently NOT approved for cancer treatment in humans. Our journey to IDE submission can be viewed with this link.
Vivos Inc. Provides IDE Submission Status
Update – Conversion to Pre-Sub Filing Accepted by the FDA
Stay up-to-date with the latest developments at RadioGel™. From groundbreaking research to new product releases, our news section has everything you need to know about our company. Read the full press release here.
Are you creative and want to see your design on our new RadioGel™ T-Shirt as we begin to launch the RadioGel® division of Vivos Inc?
Y-90 RadioGel™ is a device designed for radiation treatment of solid tumors. The Y-90 RadioGel™/Hydrogel mixture is injected directly and uniformly into tumors.
IDE submission marks our first filing with the FDA following the grant of the FDA Breakthrough Device Designation for the RadioGel® Precision Radionuclide Therapy. To read the full press releases click here. Read the Press Release
RadioGel™ is currently not approved for human use.
Also known as PRnT™, the treatment uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area, delivering therapeutic radiation from within the tumor.
We are a team dedicated to developing a safer, less invasive cancer treatment for humans and animals worldwide.
Sign up to have the latest press releases sent directly to your inbox.